Astrazeneca PLC 6-K, filed Jul 8, 2020
Astrazeneca PLC (AZN)
6-K
2020-07-08
For: 2020-07-08
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on July 8, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July
2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Lynparza approved in the EU for BRCA- mutated metastatic
pancreatic cancer
8 July 2020 07:00 BST
Lynparza approved in the EU for
BRCA-
mutated metastatic pancreatic cancer
Only PARP inhibitor approved in this disease
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck
& Co., Inc. inside the US and Canada) today announced
that Lynparza (olaparib) has been approved in the European
Union (EU) for patients with germline BRCA-mutated (gBRCAm)
metastatic pancreatic cancer.
Pancreatic cancer is a rare, life-threatening disease with the
lowest survival rate among the most common
cancers.1 Approximately
5-7% of patients with metastatic pancreatic cancer have a germline
BRCA mutation.2
The approval by the European Commission was based on results from
the Phase III POLO trial, which were published
in The
New England Journal of Medicine. It follows the recommendation for
approval by the Committee
for Medicinal Products for Human Use of the European Medicines
Agency.
Hedy L. Kindler, Co-Principal Investigator of the POLO trial and
Professor of Medicine, University of Chicago Medicine, said:
"Today's approval opens the door to a new era of biomarker-led care
for patients with metastatic pancreatic cancer in the EU, which has
the highest incidence of any region
globally. Lynparza now provides clinicians with a targeted,
well-tolerated treatment option for patients with germline
BRCA-mutated metastatic pancreatic cancer."
Dave Fredrickson, Executive Vice President, Oncology Business Unit,
said: "Patients with metastatic pancreatic cancer historically have
faced poor outcomes due to the aggressive nature of the disease and
few treatment advances have been made over the last few decades. In
the POLO trial, Lynparza nearly doubled median progression-free
survival versus placebo after 1st-line chemotherapy for patients
with germline BRCA-mutated metastatic pancreatic cancer. This
approval underscores the importance of testing all patients for
germline BRCA mutations at the time of diagnosis, as it will help
inform personalised treatment options for patients in the
EU."
Roy Baynes, Senior Vice President and Head of Global Clinical
Development, Chief Medical Officer, MSD Research Laboratories,
said: "MSD and AstraZeneca are committed to advancing research into
the treatment of patients with challenging types of cancer,
including those with metastatic pancreatic
cancer. Lynparza is now the only approved PARP inhibitor
in biomarker-selected patients with metastatic pancreatic cancer.
We look forward to making this targeted treatment option
available for patients across the EU as quickly as
possible."
The POLO trial demonstrated that Lynparza nearly doubled the time patients with gBRCAm
metastatic pancreatic cancer lived without disease progression or
death to a median of 7.4 months versus 3.8 months on placebo. The
safety and tolerability profile of Lynparza in the trial was consistent with previous
trials.
Lynparza is indicated as
monotherapy for the maintenance treatment of adult patients with
germline BRCA1/2 mutations who have metastatic adenocarcinoma of
the pancreas and have not progressed after a minimum of 16 weeks of
platinum treatment within a 1st-line chemotherapy
regimen.
Lynparza is approved in the
US and several other
countries as a 1st-line maintenance treatment for patients with
gBRCAm metastatic pancreatic cancer based on the Phase III POLO
trial, with ongoing regulatory reviews in other
regions.
Pancreatic cancer
Pancreatic cancer is a deadly cancer with a high unmet medical
need. Globally, pancreatic
cancer is the 11th-most commonly occurring
cancer and
the seventh leading cause of cancer death.3,4 There
were approximately 460,000 new cases worldwide in
2018.1 As
there are often no symptoms, or symptoms may be non-specific in the
early stages, it is most commonly diagnosed at an incurable
stage.5,6
Around 80% of pancreatic cancer patients are diagnosed when the
disease has metastasised, at which point average survival is less
than a year.7 Despite
advances, few improvements have been made in diagnosis and
treatment in the past few decades.8 Current
treatment is surgery (for which approximately only 10-20% of
patients are eligible), chemotherapy and radiotherapy, highlighting
a critical unmet medical need for more effective treatment
options.9
POLO
POLO is a randomised, double-blinded, placebo-controlled,
multi-centre Phase III trial of Lynparza tablets (300mg twice daily) as maintenance
monotherapy versus placebo. The trial randomised 154 patients with
gBRCAm metastatic pancreatic cancer whose disease had not
progressed on 1st-line platinum-based chemotherapy. Patients were
randomised (3:2) to receive Lynparza or placebo until disease progression. The
primary endpoint was progression-free survival and key secondary
endpoints included overall survival, time to second disease
progression, overall response rate and health-related quality of
life.
BRCA mutations
BRCA1 and BRCA2 (breast cancer susceptibility genes 1/2) are human
genes that produce proteins responsible for repairing damaged DNA
and play an important role in maintaining the genetic stability of
cells. When either of these genes is mutated, or altered, such that
its protein product either is not made or does not function
correctly, DNA damage may not be repaired properly, and cells
become unstable. As a result, cells are more likely to develop
additional genetic alterations that can lead to
cancer.
Lynparza
Lynparza (olaparib) is a
first-in-class PARP inhibitor and the first targeted treatment to
block DNA damage response (DDR) in cells/tumours harbouring a
deficiency in homologous recombination repair, such as mutations in
BRCA1 and/or BRCA2. Inhibition of PARP
with Lynparza leads
to the trapping of PARP bound to DNA single-strand breaks, stalling
of replication forks, their collapse and the generation of DNA
double-strand breaks and cancer cell
death. Lynparza is
being tested in a range of PARP-dependent tumour types with defects
and dependencies in the DDR pathway.
Lynparza is currently
approved in a number of countries, including those in the EU, for
the maintenance treatment of platinum-sensitive relapsed ovarian
cancer. It is approved in the US, the EU, Japan, China, and several
other countries as 1st-line maintenance treatment of BRCA-mutated
advanced ovarian cancer following response to platinum-based
chemotherapy. It is also approved in the US as a 1st-line
maintenance treatment with bevacizumab for patients with homologous
recombination deficiency positive advanced ovarian
cancer. Lynparza is approved in the US, Japan, and a number
of other countries for gBRCAm, HER2-negative, metastatic breast
cancer, previously treated with chemotherapy; in the EU, this
includes locally advanced breast cancer. It is also approved in the
US and several other countries for the treatment of gBRCAm
metastatic pancreatic cancer. Lynparza is approved in the US for homologous
recombination repair gene-mutated metastatic castration-resistant
prostate cancer. Regulatory reviews are underway in several regions
for ovarian, breast, pancreatic and prostate
cancers.
Lynparza, which is being
jointly developed and commercialised by AstraZeneca and MSD, has
been used to treat over 30,000 patients
worldwide. Lynparza has the broadest and most advanced clinical
trial development programme of any PARP inhibitor, and AstraZeneca
and MSD are working together to understand how it may affect
multiple PARP-dependent tumours as a monotherapy and in combination
across multiple cancer types. Lynparza is the foundation of AstraZeneca's
industry-leading portfolio of potential new medicines targeting DDR
mechanisms in cancer cells.
The AstraZeneca and MSD strategic oncology
collaboration
In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth,
NJ, US, known as MSD outside the US and Canada, announced a global
strategic oncology collaboration to co-develop and
co-commercialise Lynparza, the world's first PARP inhibitor,
and Koselugo (selumetinib), a MEK inhibitor, for multiple
cancer types. Working together, the companies will
develop Lynparza and Koselugo in combination with other potential new
medicines and as monotherapies. Independently, the companies will
develop Lynparza and Koselugo in combination with their respective PD-L1
and PD-1 medicines.
AstraZeneca in oncology
AstraZeneca has a deep-rooted heritage in oncology and offers a
quickly growing portfolio of new medicines that has the potential to transform
patients' lives and the Company's future. With six new medicines
launched between 2014 and 2020, and a broad
pipeline of small molecules and biologics in development,
the Company is committed to advance oncology as a key growth driver
for AstraZeneca focused on lung, ovarian, breast and blood cancers.
In addition to AstraZeneca's main capabilities, the Company is
actively pursuing innovative partnerships and investment that
accelerate the delivery of our strategy, as illustrated by the
investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms -
Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates - and by championing the development
of personalised combinations, AstraZeneca has the vision to
redefine cancer treatment and, one day, eliminate cancer as a cause
of death.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here
References
1. Pancreatic Cancer UK. Pancreatic cancer statistics. Available
at: www.pancreaticcancer.org.uk/statistics/ [Accessed
June 2020].
2. Golan et al. (2020). Geographic and Ethnic
Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among
Patients With Metastatic Pancreatic Cancer Screened for Entry Into
the POLO Trial. Journal of Clinical Oncology 2020; 38(13):
1442-1454.
3. Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries.
World Journal of Oncology. 2018;68(6):394-424. doi:
10.3322/caac.21492.
4. World Health Organization. IARC. (2019). Estimated number of
deaths in 2018, worldwide, both sexes, all
ages. Website available
here. [Accessed June
2020].
5. Signs and symptoms of pancreatic cancer. Available
at: www.pancreaticcancer.org.uk/information-and-support/facts-about-pancreatic-cancer/signs-and-symptoms-of-pancreatic-cancer/
[Accessed June 2020].
6. DaVee (2018). Pancreatic cancer screening in high-risk
individuals with germline genetic mutations. Gastrointestinal
Endoscopy. 87(6), pp.1443-1450.
7. Azar et al. (2019). Treatment and survival rates of stage IV
pancreatic cancer at VA hospitals: a nation-wide study. Journal of
Gastrointestinal Oncology, 10(4), pp.703-711.
8. Sheahan et al. (2018). Targeted therapies in the management of
locally advanced and metastatic pancreatic cancer: a systematic
review. Oncotarget. 9(30): 21613-21627.
9. Stunt, A. (2016). Pancreatic cancer: GPs can help prognosis by
identifying early signs. Guidelines in Practice. Available
at: www.guidelinesinpractice.co.uk/cancer/pancreatic-cancer-gps-can-help-prognosis-by-identifying-early-signs/352855.article
[Accessed June 2020].
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
08 July
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|